{"id":711,"date":"2025-03-03T22:26:35","date_gmt":"2025-03-03T22:26:35","guid":{"rendered":"https:\/\/perfusfind.com\/ic\/?p=711"},"modified":"2025-03-03T22:26:35","modified_gmt":"2025-03-03T22:26:35","slug":"a-narrative-review-on-the-future-of-ards-evolving-definitions-pathophysiology-and-tailored-management","status":"publish","type":"post","link":"https:\/\/perfusfind.com\/ic\/index.php\/2025\/03\/03\/a-narrative-review-on-the-future-of-ards-evolving-definitions-pathophysiology-and-tailored-management\/","title":{"rendered":"A narrative review on the future of ARDS: evolving definitions, pathophysiology, and tailored management"},"content":{"rendered":"

Abstract<\/h2>\n
\n

Acute respiratory distress syndrome (ARDS) is a severe complication of critical illness, characterized by bilateral lung infiltrates and hypoxemia. Its clinical and pathophysiological heterogeneity poses challenges for both diagnosis and treatment. This review outlines the evolution of ARDS definitions, discusses the underlying pathophysiology of ARDS, and examines the clinical implications of its heterogeneity. Traditional ARDS definitions required invasive mechanical ventilation and relied on arterial blood gas measurements to calculate the PaO2<\/sub>\/FiO2<\/sub>\u00a0ratio. Recent updates have expanded these criteria to include patients receiving noninvasive respiratory support, such as high-flow nasal oxygen, and the adoption of the SpO2<\/sub>\/FiO2<\/sub>\u00a0ratio as an alternative to the PaO2<\/sub>\/FiO2<\/sub>\u00a0ratio. While these changes broaden the diagnostic criteria, they also introduce additional complexity. ARDS heterogeneity\u2014driven by varying etiologies, clinical subphenotypes, and underlying biological mechanisms\u2014highlights the limitations of a uniform management approach. Emerging evidence highlights the presence of distinct ARDS subphenotypes, each defined by unique molecular and clinical characteristics, offering a pathway to more precise therapeutic targeting. Advances in omics technologies\u2014encompassing genomics, proteomics, and metabolomics\u2014are paving the way for precision-medicine approaches with the potential to revolutionize ARDS management by tailoring interventions to individual patient profiles. This paradigm shift from broad diagnostic categories to precise, subphenotype-driven care holds promise for redefining the landscape of treatment for ARDS and, ultimately, improving outcomes in this complex, multifaceted syndrome.<\/p>\n

Key Points<\/h3>\n
    \n
  1. Evolution of ARDS Definitions:<\/strong> ARDS criteria have progressed from the original 1967 description to the Berlin Definition, with recent modifications incorporating high-flow nasal oxygen (HFNO) and SpO\u2082\/FiO\u2082 ratios. While these changes improve accessibility, they add complexity by broadening patient inclusion.<\/li>\n
  2. Spatial Heterogeneity in ARDS:<\/strong> ARDS presents with heterogeneous lung involvement, with some regions experiencing severe edema and consolidation while others remain relatively normal. This variability complicates diagnosis and management, requiring individualized ventilation strategies.<\/li>\n
  3. Biological Heterogeneity and ARDS Subphenotypes:<\/strong> ARDS can be classified into direct (pulmonary) and indirect (extrapulmonary) injury types. Direct lung injury (e.g., pneumonia) primarily affects epithelial cells, whereas indirect injury (e.g., sepsis) involves endothelial dysfunction. Subphenotypes such as hyperinflammatory and hypoinflammatory ARDS have been identified, each with distinct responses to treatment.<\/li>\n
  4. Functional Heterogeneity Across ARDS Phases:<\/strong> ARDS progresses through inflammatory, exudative, and fibroproliferative phases, each influencing treatment strategies. While prone positioning is highly effective in the exudative phase, late-phase fibrosis may limit its benefits, underscoring the need for phase-specific interventions.<\/li>\n
  5. Ventilation Strategies and ARDS Subphenotypes:<\/strong> Pulmonary ARDS typically requires higher PEEP and low tidal volume ventilation due to decreased lung compliance, while extrapulmonary ARDS may tolerate slightly higher tidal volumes. The COVID-19 pandemic further highlighted ARDS heterogeneity, with early CARDS patients exhibiting high compliance, necessitating adjustments in standard ventilation strategies.<\/li>\n
  6. Individualized Ventilation Approaches:<\/strong> Personalized strategies that consider lung mechanics, driving pressure, and patient-specific responses to PEEP are essential. Overreliance on standardized approaches may result in ventilator-induced lung injury (VILI) or suboptimal oxygenation.<\/li>\n
  7. Non-Conventional Ventilation Methods:<\/strong> Alternative strategies such as airway pressure release ventilation (APRV), time-controlled adaptive ventilation (TCAV), and adaptive support ventilation (ASV) offer potential benefits but require further research to establish efficacy in ARDS management.<\/li>\n
  8. Impact of ARDS Heterogeneity on Precision Treatment:<\/strong> Advances in latent class analysis and biomarker research suggest that ARDS treatment should be stratified based on subphenotypes. Patients with hyperinflammatory ARDS may benefit from targeted anti-inflammatory therapies, whereas hypoinflammatory patients may require different therapeutic strategies.<\/li>\n
  9. Role of Omics in Future ARDS Management:<\/strong> Emerging omics technologies, including genomic and proteomic profiling, offer opportunities for precision medicine. Identifying ARDS-specific biomarkers could refine treatment decisions, improve patient outcomes, and guide novel therapeutic developments.<\/li>\n
  10. Future Directions in ARDS Research:<\/strong> Refining ARDS definitions, integrating subphenotyping into clinical practice, and leveraging precision medicine tools will be crucial in optimizing patient outcomes. Future guidelines must incorporate personalized approaches that account for the diverse presentations of ARDS.<\/li>\n<\/ol>\n

    ACCESS FULL ARTICLE HERE<\/strong><\/a><\/p>\n

    Open Access<\/b>\u00a0This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article\u2019s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article\u2019s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit\u00a0http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/a>.<\/p>\n